PT  - JOURNAL ARTICLE
AU  - Nowotny, Hanna
AU  - Auer, Matthias K.
AU  - Lottspeich, Christian
AU  - Schmidt, Heinrich
AU  - Dubinski, Ilja
AU  - Bidlingmaier, Martin
AU  - Adaway, Jo
AU  - Hawley, James
AU  - Keevil, Brian
AU  - Reisch, Nicole
TI  - Salivary profiles of 11-oxygenated androgens follow a diurnal rhythm in patients with congenital adrenal hyperplasia
AID  - 10.1101/2021.02.02.21249720
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21249720
4099  - http://medrxiv.org/content/early/2021/02/05/2021.02.02.21249720.short
4100  - http://medrxiv.org/content/early/2021/02/05/2021.02.02.21249720.full
AB  - Context Several studies have highlighted the importance of the 11-oxygenated 19-carbon (11oxC19) adrenal-derived steroids as potential biomarkers for monitoring patients with 21-hydroxylase deficiency (21OHD).Objective To analyze circadian rhythmicity of 11oxC19 steroids in saliva profiles and evaluate their relevance as potential monitoring parameters in 21OHD.Design, Setting, and Participants Cross-sectional single center study including 34 patients with classic 21OHD (men=14; women=20) and 32 BMI- and age-matched controls (men=15; women=17).Outcome Measures Salivary concentrations of the following steroids were analyzed by LC-MS/MS: 17-hydroxyprogesterone (17OHP), androstenedione (A4), testosterone (T), 11β-hydroxyandrostenedione (11OHA4) and 11-ketotestosterone (11KT).Results Similar to the previously described rhythmicity of 17OHP, 11OHA4 and 11KT concentrations followed a distinct diurnal rhythm in both patients and controls with highest concentrations in the early morning and declining throughout the day (11-OHA4: male patients Δmean = 79 %; male controls Δmean = 81%; female patients Δmean = 33 %; female controls Δmean = 91 %; 11KT: male patients Δmean = 64 %; male controls Δmean = 60 %; female patients Δmean = 49 %; female controls Δmean = 81 %). Significant correlations between the area under the curve (AUC) for 17OHP and 11KT (r(p)male = 0.741**; r(p)female = 0.842****), and 11OHA4 (r(p)male = 0.385n.s.; r(p)female = 0.527*) were observed in patients but not in controls.Conclusions Adrenal 11oxC19 androgens are secreted following a diurnal pattern. This should be considered when evaluating their utility for monitoring treatment control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer: 314061271-TRR205 to NR). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical review board of the Ludwig Maximilian University, Munich, GermanyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be provided by the corresponding author on reasonable request11β-HSD211β-hydroxysteroid dehydrogenase type 211oxC1911-oxygenated 19-carbon11OHA411β-hydroxyandrostenedione11KA411-ketoandrostenedione11KDHT11-ketodihydrotestosterone11KT11-ketotestosterone11OHT11-hydroxytestosterone21DF21-deoxycortisol21OHD21-hydroxylase deficiencyA4androstenedioneACTHadrenocorticotropic hormoneAUCarea under the curveCAHcongenital adrenal hyperplasiaCRHcorticotropin releasing hormoneCYP11B111β-hydroxylaseDHTdihydrotestosteroneGCglucocorticoidHPAhypothalamic-pituitary-axisHPGhypothalamic-pituitary-gonadalLLOQlowest limits of quantificationLP-MS/MSliquid chromatography-mass spectrometryPVNparaventricular nucleusStARsteroidogenic acute regulatory proteinSCNsuprachiasmatic nucleusTtestosteroneTARTtesticular adrenal rest tumorsUPC2-MS/MSultra-performance convergence chromatography tandem mass spectrometry